Retrophin Inc Q3 2020 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Michelle Lim Gilson - Canaccord Genuity Corp., Research Division - Analyst : Just following up on Scott's question. Do you anticipate -- I guess, what is the timing that you anticipate around the eGFR readout and I guess the timing of your potential regulatory submissions in the entire regulatory process? And then is there a clinically meaningful benefit that you're looking for in terms of eGFR as well as a statistical, I guess, statistically significant benefit?

Question: Michelle Lim Gilson - Canaccord Genuity Corp., Research Division - Analyst : Got it. And just one follow-up as well. Obviously, there are quite a few IgA nephropathy studies currently ongoing. And I'm just curious if you have any plans to evaluate sparsentan in combination with any of those agents at some point if others are approved and how you kind of think of sparsentan in -- within the IgA nephropathy landscape. I guess these patients are primarily managed with blood pressure control and so maybe how you imagine kind of that switching process. Or are you mostly targeting newly diagnosed patients? I guess could you just give us kind of an overview of how you're thinking about the market as it evolves?